RPD · Rapid7, Inc. · Stock research

Current Thesis

Rapid7's growth story ended several quarters ago. Q1 2026 (reported 2026-05-05) put revenue at $209.7M, down 0.3% year-over-year, ARR at $832M compounding in the low single digits, and management guiding Q2 2026 ARR down to roughly $820M — a sequential contraction. On a standalone basis this is an ex-growth, cash-generative security-software business, and the only reason the stock sits near $11 rather than the high single digits is the take-private process Jana Partners forced. Jana holds ~10.3% (6.76M shares, 13D 2026-02-13) with settlement room to 19.9% and a board seat (Kevin Galligan), while Goldman Sachs and JPMorgan shop the company to Advent International, Bain Capital and EQT. The fresh tell is where sell-side targets have moved: DA Davidson's $6.50 standalone floor (2026-06-02) has been overtaken by Mizuho $11 (2026-07-15), Truist $10 (2026-07-21) and Morgan Stanley $9 (2026-07-21, cut to Underweight). The desks are now marking to a deal-probability band that brackets the tape rather than to fundamentals. This is a maturing event-driven special situation into a binary Q2 print (~2026-08-05), not a momentum trade.

Bullish and bearish views on Rapid7, Inc.

The model's bull view on Rapid7, Inc. (RPD), in brief: LBO math the sponsors are underwriting. FY2026 guide (2026-05-05) is $836–842M revenue and $125–135M free cash flow against a ~$731M market cap at $10.94 (2026-07-08): sub-1x market-cap-to-ARR and a high-teens FCF yield — recurring revenue, positive cash, depressed multiple, the… The bear view: The business is shrinking. Q1 2026 revenue -0.3% YoY, product revenue roughly flat, services down, and Q2 ARR guided to ~$820M from $832M. Detection & response (~55% of ARR) grows ~7% but the legacy vulnerability-management base offsets it. A desk just moved the other way.… Both cases follow in full.

Bull Case

• LBO math the sponsors are underwriting. FY2026 guide (2026-05-05) is $836–842M revenue and $125–135M free cash flow against a ~$731M market cap at $10.94 (2026-07-08): sub-1x market-cap-to-ARR and a high-teens FCF yield — recurring revenue, positive cash, depressed multiple, the exact profile private equity takes out.
• Committed activist with a path. Jana built ~10.3% (13D 2026-02-13), disclosed buying at $15.71 (2025-11-28), won a board seat, and can accumulate to 19.9% — an owner marking fair value well above the current tape and pushing toward a sale.
• Bankers engaged, multiple named bidders. Goldman Sachs and JPMorgan are running the process; Advent, Bain and EQT are in early-stage talks and Cannae Holdings is reportedly weighing a PE partnership. Several credible sponsors reduce single-bidder risk.
• Sell-side re-rating toward a deal. Truist to $10 and Mizuho to $11 (2026-07-15/21) lifted targets off the June $6.50–6.67 fundamental band, narrowing the air beneath the price that the newest PTs implied only six weeks earlier.
• Supportive backdrop. Second-half small-cap tape is being driven by buyouts (Benzinga small-cap roundup, 2026-07-21); event-driven names with real sponsor interest are in favor.

Bear Case

• The business is shrinking. Q1 2026 revenue -0.3% YoY, product revenue roughly flat, services down, and Q2 ARR guided to ~$820M from $832M. Detection & response (~55% of ARR) grows ~7% but the legacy vulnerability-management base offsets it.
• A desk just moved the other way. Morgan Stanley cut RPD to Underweight with a $9 target (2026-07-21) — with a binary print ten days out and the stock near $11, at least one desk reads the risk/reward as negative.
• "May not lead to a deal." Every report carries the caveat that talks collapse and Rapid7 stays independent. That headline reprices the stock to the $9 standalone / $6.50 deep-value band with no warning.
• Financing-cost sensitivity. LBO debt terms cap the achievable bid; a higher-for-longer rate path compresses the premium a sponsor can pay.
• No trend to ride. RPD is a range-bound laggard decoupled from the accelerating cyber leaders; there is no momentum leg here, only deal odds.

Setup & Price Structure

RPD has built a multi-month shelf in the ~$10.60–11.20 zone off the 52-week low of $4.97, trading near $10.94 as of 2026-07-08 — coiled and range-bound rather than trending. The newest analyst targets bracket the tape almost exactly: Morgan Stanley $9, Truist $10, Mizuho $11 (all 2026-07-15/21). That tight cluster is the market pricing a deal-probability-weighted value, which leaves the tape with little standalone momentum and most of the outcome binary. There is no mania here and no peak-retail froth; the trap runs the other way. Buying the break of the shelf on the hope the deal still closes is the averaging-down mistake the playbook forbids. A clean fresh entry exists only as a small event probe near the shelf, sized for a binary, with no add on weakness.

Catalyst Calendar (next 30 days)

• Undated / any day: M&A headline from the Goldman/JPMorgan process (Advent, Bain, EQT, Cannae). A signed take-private or a "remain independent" statement is the dominant catalyst and carries no fixed date.
• Undated: Jana 13D/A accumulation disclosures up to the 19.9% cap — each incremental buy is a conviction signal on deal odds.

Elapsed catalysts

• ~2026-08-05 (est.): Q2 2026 earnings and updated ARR. Binary. ARR already guided to ~$820M; a further cut deepens the ex-growth problem, while any explicit process commentary is the swing factor. (passed 4d ago)

What Would Change Our Mind

• A signed take-private at a premium (a bid in the low-to-mid teens) confirms the thesis and re-rates the stock — though at announcement most of the move is already realized.
• A formal "remain independent" / process-terminated announcement collapses the premium toward the $9 Morgan Stanley standalone and the $6.50 DA Davidson deep-value floor; thesis dead.
• A weekly close below $9.50 breaks the take-private shelf and confirms the premium bleeding out, independent of any headline.
• Another ARR cut on the 2026-08-05 print erodes the standalone valuation floor that limits downside if talks fail.
• Net-new ARR re-acceleration (not expected near-term) would restore a fundamental leg and turn this from a pure event probe into a value-plus-catalyst name.

Correlation Notes

• Decoupled from cyber leaders. RPD trades on deal odds; its beta to the accelerating cyber tape (PANW, CRWD, ZS, S) is low, so it neither confirms nor rides the theme's strength.
• Tied to PE financing conditions. As an LBO candidate, RPD's premium tracks credit spreads and the rate path — higher-for-longer compresses the achievable bid; easing supports it.
• Take-private comp set. Thoma Bravo's serial cyber take-privates set the valuation and sentiment comps for sub-scale security assets; RPD's deal-multiple expectations move with those precedents.
• Event-driven small-cap cohort. Sentiment correlates with the broader small-cap buyout wave (Benzinga roundup, 2026-07-21) more than with software fundamentals.